1
|
Assessment of CD40 and CD40L expression in rheumatoid arthritis patients, association with clinical features and DAS28. Clin Exp Med 2019; 19:427-437. [PMID: 31313080 DOI: 10.1007/s10238-019-00568-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Accepted: 07/08/2019] [Indexed: 01/09/2023]
Abstract
The predominance of the effector mechanisms by CD4 + T cells is a characteristic of inflammatory autoimmune diseases such as rheumatoid arthritis (RA). The CD40/CD40L costimulatory pathway contributes to these pathogenic mechanisms by promoting autoantibody production and inflammation. Aberrant expression of CD40 and CD40L in RA patients has been shown, the latter prevailing in females. However, contrasting results have emerged regarding the clinical associations of these findings. We determined the association of CD40 and CD40L expression with the clinical activity evaluated through DAS28 in RA patients. A total of 38 female RA patients and 10 age- and sex-matched control subjects were included. CD40 and CD40L mRNA expression was quantified by real-time qPCR, cell surface proteins were determined by flow cytometry, and protein soluble forms were determined by ELISA. The expansion of a CD4 + T cell subpopulation expressing CD40 was identified in the RA group. In addition, high frequencies of CD4 + CD40L + T cells expressing high levels of CD40L, increased levels of sCD40L and overexpression of CD40L mRNA were observed in these patients. Moreover, there was a gradual increase in CD40L when data were stratified according to DAS28, except for very active patients. No correlation was observed between the levels of mRNA, cell surface protein and soluble protein of CD40 and CD40L with the clinical features of RA patients. There is an altered expression of CD40L in female RA patients in association with clinical activity assessed by DAS28, these findings support the evidence that suggests CD40L as a marker of clinical activity.
Collapse
|
2
|
Luan J, Zhang K, Yang P, Zhang Y, Feng F, Zhu YM, Zhu P, Chen ZN. The combination of FK506 and an anti-CD147 mAb exerts potential therapeutic effects on a mouse model of collagen-induced arthritis. Mol Immunol 2018; 101:1-9. [PMID: 29852454 DOI: 10.1016/j.molimm.2018.05.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 05/02/2018] [Accepted: 05/14/2018] [Indexed: 01/16/2023]
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, and excessive T lymphocyte activation plays a critical role in the development of inflammation. CD147 is an antigen related to T cell activation, CD147 blockade exerts beneficial effects on RA. FK506, also known as tacrolimus, exerts strong immunosuppressive effects by inhibiting T cell activation. In this study, RL73 (an anti-mouse CD147 functional-grade purified antibody) and FK506 were co-administered to mice with collagen-induced arthritis (CIA). As expected, the combination of these two drugs produced superior therapeutic effects than either drug alone and enabled the administration of each drug at a lower dose. Moreover, joint damage and destruction were significantly improved in mice injected with both FK506 and RL73 compared with mice injected with either agent alone. These effects might have been observed because the proportions of CD4 + T and CD8 + T cells in the mouse spleen of the combination regimen were clearly decreased compared with each monotherapy. In addition, the proportions of Th2 subsets in the mouse spleen and peripheral blood were clearly increased, and the serum levels of the cytokines interleukin 4 (IL-4) and IL-10 were markedly increased in mice treated with the combination therapy compared with the other groups of mice. The splenic total number of T lymphocytes also showed that the inhibition of T lymphocytes was the most obvious in the combined treatment group. Based on the results from the present study, combining FK506 and the anti-CD147 mAb might be a new practical therapeutic option for the treatment of RA.
Collapse
Affiliation(s)
- Jing Luan
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Cell Engineering Research Center & Department of Cell Biology, Fourth Military Medical University , Xi'an, 710032, China; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China
| | - Kui Zhang
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China
| | - Peng Yang
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Cell Engineering Research Center & Department of Cell Biology, Fourth Military Medical University , Xi'an, 710032, China
| | - Yang Zhang
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Cell Engineering Research Center & Department of Cell Biology, Fourth Military Medical University , Xi'an, 710032, China.
| | - Fei Feng
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Cell Engineering Research Center & Department of Cell Biology, Fourth Military Medical University , Xi'an, 710032, China
| | - Yu-Meng Zhu
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Cell Engineering Research Center & Department of Cell Biology, Fourth Military Medical University , Xi'an, 710032, China
| | - Ping Zhu
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
| | - Zhi-Nan Chen
- National Translational Science Center for Molecular Medicine, Xi'an, 710032, China; Cell Engineering Research Center & Department of Cell Biology, Fourth Military Medical University , Xi'an, 710032, China.
| |
Collapse
|
3
|
A critical epitope in CD147 facilitates memory CD4 + T-cell hyper-activation in rheumatoid arthritis. Cell Mol Immunol 2018; 16:568-579. [PMID: 29563614 PMCID: PMC6804595 DOI: 10.1038/s41423-018-0012-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 02/01/2018] [Accepted: 02/01/2018] [Indexed: 12/20/2022] Open
Abstract
The abnormal activation of CD4+CD45RO+ memory T (Tm) cells plays an important role in the pathogenesis of rheumatoid arthritis (RA). Previous studies have shown that CD147 participates in T-cell activation. However, it remains unclear whether CD147 is involved in abnormal Tm-cell activation in RA patients. In this study, we demonstrated that CD147 was predominantly upregulated in Tm cells derived from RA patients. The anti-CD147 mAb 5A12 specifically inhibited Tm-cell activation and proliferation and further restrained osteoclastogenesis. Using a structural-functional approach, we depicted the interface between 5A12 and CD147. This allowed us to identify two critical residues, Lys63 and Asp65, as potential targets for RA treatment, as the double mutation K63A/D65A inhibited Tm-cell activation, mimicking the neutralization by 5A12. This study provides not only a theoretical basis for a "CD147-Tm/Osteoclast-RA chain" for the potential prevention and treatment of RA or other T-cell-mediated autoimmune diseases but also a new target for related drug design and development.
Collapse
|
4
|
Luo Q, Deng Z, Xu C, Zeng L, Ye J, Li X, Guo Y, Huang Z, Li J. Elevated Expression of Immunoreceptor Tyrosine-Based Inhibitory Motif (TIGIT) on T Lymphocytes is Correlated with Disease Activity in Rheumatoid Arthritis. Med Sci Monit 2017; 23:1232-1241. [PMID: 28282368 PMCID: PMC5358849 DOI: 10.12659/msm.902454] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Background It is well known that lymphocytes play an important role in rheumatoid arthritis (RA). T cell immunoreceptors with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (TIGIT) have immunosuppressive co-stimulatory molecules that mediate inhibitory effects, but their roles in RA are poorly understood. Material/Methods Were recruited 76 patients with RA and 33 healthy controls (HC). Clinical manifestations, laboratory measurements, physical examination, and medical history of RA patients were recorded. The expression of TIGIT on CD3+ T lymphocytes, B lymphocytes, monocytes, neutrophils, CD3+CD4+ T lymphocytes, and CD3+CD8+ T lymphocytes was determined using flow cytometry. The expression of TIGIT on T lymphocytes in patients with RA was further analyzed to investigate its correlations with markers of autoimmune response, inflammation, and disease activity in RA. Results Compared with HC, the expression levels of TIGIT on CD3+CD4+ T lymphocytes and CD3+CD8+ T lymphocytes were significantly increased in patients with RA (P < 0.01). The frequency of TIGIT-expressing CD3+CD4+ T lymphocytes was positively correlated with RF, increased ACPA, ESR, and CRP levels. The frequency of TIGIT-expressing CD3+CD8+ T lymphocytes was positively correlated with RF and ESR levels. Furthermore, the expression level of TIGIT on CD3+CD4+ T lymphocytes was positively correlated with the DAS28 score in RA. Conclusions The expression levels of TIGIT on T lymphocytes were elevated and correlated with disease activity in RA.
Collapse
Affiliation(s)
- Qing Luo
- Department of Clinical laboratory, The 1st Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Zhen Deng
- College of Medicine, Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Chuxin Xu
- College of Medicine, Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Lulu Zeng
- College of Medicine, Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Jianqing Ye
- College of Medicine, Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Xue Li
- College of Medicine, Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Yang Guo
- Department of Clinical Laboratory Medicine, The 1st Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Zikun Huang
- Department of Clinical Laboratory Medicine, The 1st Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland)
| | - Junming Li
- Department of Clinical Laboratory Medicine, The 1st Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (mainland)
| |
Collapse
|
5
|
Guo Y, Xing E, Song H, Feng G, Liang X, An G, Zhao X, Wang M. Therapeutic effect of dioscin on collagen-induced arthritis through reduction of Th1/Th2. Int Immunopharmacol 2016; 39:79-83. [DOI: 10.1016/j.intimp.2016.06.029] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Revised: 06/24/2016] [Accepted: 06/24/2016] [Indexed: 12/19/2022]
|
6
|
Mancheño-Corvo P, Menta R, del Río B, Franquesa M, Ramírez C, Hoogduijn MJ, DelaRosa O, Dalemans W, Lombardo E. T Lymphocyte Prestimulation Impairs in a Time-Dependent Manner the Capacity of Adipose Mesenchymal Stem Cells to Inhibit Proliferation: Role of Interferon γ, Poly I:C, and Tryptophan Metabolism in Restoring Adipose Mesenchymal Stem Cell Inhibitory Effect. Stem Cells Dev 2015; 24:2158-70. [PMID: 26058889 DOI: 10.1089/scd.2014.0508] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The immunomodulatory properties of mesenchymal stem/stromal cells (MSCs) make them an attractive therapeutic tool to treat chronic inflammatory diseases, such as rheumatoid arthritis or Crohn's disease. These indications are characterized by a chronic activation of immune cells that perpetuates the disease. In vitro, when adipose mesenchymal stem cells (ASCs) are cultured with T lymphocytes at the time of stimulation, their proliferation is inhibited. However, these experimental settings do not necessarily fit with what ASCs will face in inflammatory conditions in vivo, where ASCs will likely encounter and interact with already activated immune cells which might affect their immunomodulatory capacity. In most in vitro studies, MSCs have been cultured with peripheral blood mononuclear cells at the time of lymphocyte stimulation and information about the interaction between MSCs and prestimulated lymphocytes in vitro is scarce. Therefore, a better understanding of the capacity of MSCs to modulate the responses of preactivated immune cells is needed. In this study we focused on the effects of ASCs on prestimulated lymphocytes and systematically investigated the potential mechanisms involved. We report that prestimulation of T lymphocytes 48 h before the coculture with ASCs impairs the capacity of ASCs to inhibit proliferation. Preactivation of ASCs with interferon γ or the toll-like receptor ligand Poly I:C, but not other stimuli tested, enhanced the ability to inhibit the proliferation of 48 h-stimulated T lymphocytes. The inhibitory effect of ASCs was shown to be time dependent and mediated through the actual magnitude of tryptophan degradation by indoleamine 2,3-dioxygenase.
Collapse
Affiliation(s)
| | - Ramón Menta
- 1 TiGenix SAU, Parque Tecnológico de Madrid , Madrid, Spain
| | - Borja del Río
- 1 TiGenix SAU, Parque Tecnológico de Madrid , Madrid, Spain
| | - Marcella Franquesa
- 2 Nephrology and Transplantation, Internal Medicine, Erasmus Medical Center , Rotterdam, the Netherlands
| | | | - Martin J Hoogduijn
- 2 Nephrology and Transplantation, Internal Medicine, Erasmus Medical Center , Rotterdam, the Netherlands
| | - Olga DelaRosa
- 1 TiGenix SAU, Parque Tecnológico de Madrid , Madrid, Spain
| | | | | |
Collapse
|